As medical treatment may be necessary, it is essential to receive an accurate diagnosis as early as possible. A person may wish to contact a doctor if they have an existing SLE diagnosis and have ...

Pericarditis occurs in 15% to 30% of patients with SLE, a chronic autoimmune disease that causes the body's immune system to attack its own tissues. "It is well known that in the general population, ...

A new study finds that ChatGPT4 provides answers to lupus patient questions as effectively as rheumatologists, excelling in ...

For patients with systemic lupus erythematosus (SLE) and pericarditis, recurrence of pericarditis occurs in more than 20% of patients and associated factors include younger age, prednisone treatment, ...

Prolonged remission was observed in 72% of patients with systemic lupus erythematosus (SLE) who were treated with a consistent 200 mg daily dose of hydroxychloroquine. The mean weight-adjusted ...

A cohort study finds that hydroxychloroquine use in cutaneous lupus erythematosus reduces the risk of developing systemic ...

Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...

Although SLE and psoriasis—an inflammatory skin condition ... 2024.4991 Provided by UT Southwestern Medical Center ...

ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment ...

Fast Track Designation is a process designed to facilitate development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. About ADI-001 ADI-001 ...